DOT1L-AF10-mediated H3K79me3 promotes NF-kB p65-dependent inflammatory activation in endothelial cells

This study demonstrates that DOT1L-mediated H3K79me3 enrichment at the *RELA* promoter, facilitated by AF10 and AF9, drives NF-κB p65-dependent inflammatory activation in endothelial cells, identifying this epigenetic mechanism as a potential therapeutic target for atherosclerosis.

The Gist

The Big Picture: A Traffic Jam in Your Arteries

Imagine your blood vessels are like a busy highway system. Under normal conditions, blood flows smoothly (like cars on a clear highway). But sometimes, at sharp turns or intersections, the flow gets messy, turbulent, and chaotic. In the body, this is called "Disturbed Flow."

When blood flow gets messy, the cells lining your arteries (the endothelial cells) get stressed. They start sounding the alarm, releasing chemicals that cause inflammation. This is the first step toward atherosclerosis (hardening of the arteries), which can lead to heart attacks and strokes.

This paper asks a simple question: What is the "switch" inside these cells that turns on the inflammation alarm when the traffic gets messy?

The scientists found that the switch is an epigenetic "molecular highlighter" called DOT1L.

---

The Characters in the Story

1. The Highway (The Artery): The place where blood flows.
2. The Traffic Cop (NF-κB p65): A protein that acts like a foreman. When activated, it tells the cell to build "roadblocks" (inflammatory molecules) that attract immune cells, causing swelling and plaque.
3. The Highlighter (DOT1L): An enzyme that acts like a high-lighter pen. It marks specific pages in the cell's instruction manual (DNA) to say, "Read this part loud and clear!"
4. The Instruction Manual (DNA): The blueprint for the cell.
5. The Eraser (FBXL10): A protein that can wipe out the highlights.

---

What the Scientists Discovered

1. The Messy Traffic Turns on the Highlighter

When the scientists simulated "messy traffic" (disturbed flow) or exposed artery cells to inflammatory signals (like TNF-α), they saw a change. The cells started producing way more DOT1L.

Think of DOT1L as a highlighter that suddenly starts scribbling all over the instruction manual. Specifically, it was highlighting a very specific page: the page that contains the instructions for building the Traffic Cop (NF-κB p65).

2. The "Highlight" Makes the Alarm Louder

In the cell's nucleus, the DNA is wrapped around spools called histones. DOT1L puts a chemical mark (called H3K79me3) on these spools.

• Without the mark: The instruction manual is closed or quiet.
• With the mark: The manual is wide open, and the cell reads the "NF-κB p65" instructions over and over again.

Because the cell is reading these instructions so loudly, it produces massive amounts of the NF-κB p65 protein. This protein then runs around the cell, turning on other genes that cause inflammation, attract sticky immune cells (monocytes), and damage the artery wall.

3. The Team Behind the Highlighter

The paper also found that DOT1L doesn't work alone. It has a crew (called the DotCom complex).

• AF10 and AF9: These are like the assistants who help the highlighter find the right page and stick to it. The study found these assistants increased when traffic got messy.
• AF17: This is the "brake" pedal. It usually tries to stop the highlighter from working too hard. The study found that under stress, the cell actually removed this brake pedal, letting the highlighter go wild.

4. The "Off Switch" (The Solution)

The most exciting part of the study is what happened when they tried to stop the highlighter.

The scientists used a drug called SYC-522 (a DOT1L inhibitor). Imagine this drug as a piece of tape over the highlighter pen.

• Result: When they taped the highlighter, the "NF-κB p65" instructions were no longer read loudly.
• The Outcome: The cell stopped making so much of the inflammatory Traffic Cop. The artery cells calmed down, stopped attracting sticky immune cells, and returned to a healthier state.

Crucially, they found that this drug didn't just stop the Traffic Cop from moving (which is how most current drugs work); it stopped the cell from building so many Traffic Cops in the first place. It fixed the problem at the source code level.

---

Why This Matters

For a long time, doctors have tried to stop inflammation by blocking the "Traffic Cop" (NF-κB) after it has already been activated. But this is like trying to stop a fire after the house is already burning.

This paper suggests a new strategy: Don't just fight the fire; stop the arsonist from lighting the match.

By using a drug to block the DOT1L highlighter, we can prevent the cell from ever turning on the inflammation alarm in the first place. This could be a powerful new way to treat or prevent heart disease, keeping our arterial "highways" clear and smooth.

Summary Analogy

• Disturbed Blood Flow = A traffic jam.
• DOT1L = A highlighter pen that marks the "Inflammation" chapter in the cell's book.
• NF-κB p65 = The alarm system that gets turned on because the book was highlighted.
• The Drug (SYC-522) = Taping the highlighter shut so the alarm never goes off.

The study proves that if you stop the highlighter, you stop the inflammation, potentially saving hearts from clogging up.

Technical Summary

1. Problem Statement

Atherosclerosis is a chronic inflammatory disease driven by endothelial dysfunction, often initiated by disturbed blood flow (D-Flow) and pro-inflammatory cytokines like TNF-α. The transcription factor NF-κB p65 (encoded by RELA) is a central regulator of this inflammatory response. While the canonical signaling pathway of NF-κB activation is well-characterized, the epigenetic mechanisms governing the transcriptional upregulation of RELA in response to atherogenic stimuli remain unclear. Specifically, the role of DOT1L (Disruptor of Telomeric Silencing 1-Like), a histone methyltransferase that catalyzes methylation of Histone H3 at Lysine 79 (H3K79), in endothelial inflammation has not been fully elucidated.

2. Methodology

The study employed a multi-faceted approach combining in vivo models, in vitro cell culture, advanced epigenetic profiling, and pharmacological/genetic interventions:

• In Vivo Models:
  • Partial Carotid Artery Ligation: Performed in HFD-fed C57BL/6 mice to induce D-Flow and neointima formation. Tissues were analyzed via immunohistochemistry (IHC) and immunofluorescence (IF).
  • Ex Vivo Rat Aortic Rings: Used to assess spatial distribution of markers in regions of D-Flow (lesser curvature) vs. Stable Flow (S-Flow, greater curvature) and to test drug efficacy in intact tissue.
• In Vitro Models:
  • 3D-Printed Microchannels: Human coronary artery models (60° bifurcation) were used to expose EA.hy926 and HUVEC cells to physiological D-Flow and S-Flow conditions.
  • Chemical Stimulation: Cells were treated with TNF-α (10 ng/mL) to induce inflammatory phenotypes.
• Epigenetic Profiling:
  • CUT&RUN Sequencing: Performed on HUVECs (± TNF-α) to map genome-wide H3K79me3 distribution. Data was analyzed for peak calling (MACS2), chromosomal coverage, and promoter enrichment.
  • CUT&RUN-qPCR: Validated specific enrichment at the RELA promoter.
  • RNA-seq Analysis: Utilized public data (GSE121958) to correlate H3K79me3 changes with gene expression dynamics.
• Intervention Strategies:
  • Pharmacological Inhibition: Use of SYC-522, a specific DOT1L catalytic inhibitor.
  • Genetic Manipulation: siRNA-mediated knockdown of DOT1L and overexpression of FBXL10 (KDM2B), a specific H3K79me2/3 demethylase.
• Assays: Western blotting, qPCR, immunostaining, and monocyte adhesion assays (using DiI-labeled THP-1 cells).

3. Key Contributions & Results

A. Upregulation of DOT1L and H3K79me3 in Atherogenic Conditions

• In Vivo: Partial carotid ligation and D-Flow regions in rat aortas showed significantly elevated expression of DOT1L and H3K79me3 in endothelial cells (ECs) compared to controls or S-Flow regions.
• In Vitro: Both D-Flow and TNF-α stimulation increased DOT1L expression and global H3K79me3 levels in ECs. Notably, levels of H3K79me and H3K79me2 remained unchanged, indicating a specific shift toward the H3K79me3 mark.
• DotCom Complex Dynamics: The study identified a specific reconfiguration of the DOT1L-containing complex (DotCom):
  • Upregulated: AF10 (MLLT10) and AF9 (MLLT3), which recruit DOT1L.
  • Downregulated: AF17 (MLLT6), which normally promotes DOT1L nuclear export and suppresses methylation.
  • This shift creates a favorable environment for enhanced H3K79me3 deposition.

B. Selective Enrichment at the RELA Promoter

• Genome-wide Analysis: CUT&RUN sequencing revealed that while H3K79me3 is broadly distributed, TNF-α stimulation caused selective, focal enrichment at the promoter region of the RELA (NF-κB p65) gene.
• Validation: CUT&RUN-qPCR confirmed a time-dependent increase in H3K79me3 at the RELA promoter (4h and 24h post-TNF-α).
• Specificity: No significant H3K79me3 enrichment changes were observed at the promoters of other inflammatory genes like ICAM1 or VCAM1, suggesting RELA is the primary direct target of this epigenetic mechanism.

C. Mechanism: Epigenetic Priming of NF-κB p65

• Transcriptional Regulation: The increased H3K79me3 at the RELA promoter correlated with increased RELA mRNA and protein levels.
• Independence from Canonical Signaling: Crucially, the study demonstrated that DOT1L inhibition (via SYC-522) or knockdown reduced NF-κB p65 protein expression without altering the canonical activation cascade:
  • Phosphorylation of IKKβ (S176/180) remained unchanged.
  • Phosphorylation and degradation of IκBα (S32) remained unchanged.
  • Conclusion: DOT1L-mediated H3K79me3 acts as a transcriptional priming mechanism that increases the amount of NF-κB p65 available, rather than just activating existing pools of the protein.

D. Functional Consequences and Therapeutic Potential

• Inflammatory Phenotype: Inhibition of DOT1L (SYC-522) or overexpression of FBXL10 (demethylase) resulted in:
  • Reduced NF-κB p65 expression and nuclear localization.
  • Downregulation of downstream inflammatory markers (ICAM1, VCAM1).
  • Restoration of eNOS expression (a marker of endothelial health).
  • Significant reduction in monocyte adhesion to endothelial cells.
• Rescue in D-Flow: SYC-522 treatment effectively reversed the pro-inflammatory phenotype induced by disturbed flow in both 3D microchannels and ex vivo aortic rings.

4. Significance

• Novel Epigenetic Mechanism: This study identifies H3K79me3 as a critical epigenetic switch that drives endothelial inflammation by directly upregulating the transcription of RELA. It shifts the understanding of NF-κB regulation from purely post-translational (phosphorylation) to include transcriptional epigenetic control.
• Therapeutic Target: It validates DOT1L and its catalytic activity as a promising therapeutic target for atherosclerosis. Unlike broad NF-κB inhibitors which may impair immune defense, targeting DOT1L specifically reduces the production of the inflammatory driver (p65) while sparing the canonical signaling machinery, potentially offering a more balanced therapeutic approach.
• Complex Dynamics: The study highlights the importance of the DotCom complex composition (AF10/AF9 up, AF17 down) in modulating DOT1L activity in vascular disease, providing new targets for intervention.

In summary, the paper establishes that DOT1L-mediated H3K79me3 serves as a master regulator of endothelial inflammation by epigenetically priming the RELA gene, making it a viable target for mitigating NF-κB-driven atherosclerosis.